Abstract
Background: Immunity and clinical protection induced by mRNA vaccines against SARS-CoV-2 have been shown to decline overtime. To gather information on the immunity profile deemed sufficient in protecting against hospitalization, we tested IgG levels, interferon-gamma (IFN-γ) secretion, and neutralizing antibodies 180 days (d180) after the second shot of BNT162b vaccine, in HW.
Methods: A total of 392 subjects were enrolled. All received BioNTech/Pfizer from February 2020 to April 2021. The vaccine-specific humoral response was quantitatively determined by testing for IgG anti-S1 domain of SARS-CoV-spike protein. Live virus microneutralization (MN) was evaluated by an assay performing incubation of serial 2-fold dilution of human serum samples, starting from 1:10 to 1:5120, with an equal volume of Wuhan strain and Delta VOC viral solution and assessing the presence/absence of a cytopathic effect. SARS-CoV-2-spike protein-specific T-cell response was determined by a commercial IFN-γ release assay.
Results: In 352 individuals, at d180, IgG levels decreased substantially but no results below the assay’s positivity threshold were observed. Overall, 22 naive (8.1%) had values above the highest threshold. Among COVID-naive, the impact of age, which was observed at earlier stages, disappeared at d180, while it remained significant for 81 who had experienced a previous infection. Following the predictive model of protection by Khoury, we transformed the neutralizing titers in IU/ml and used a 54 IU/ml threshold to identify subjects with 50% protective immunity. Overall, live virus MN showed almost all subjects with previous exposure to SARS-CoV-2 neutralized the virus as compared to 33% of naive double-dosed subjects ( p < 0.0001). All previously exposed subjects had strong IFN-γ secretion (>200 mIU/ml); among 271 naive, 7 (2.58%) and 17 (6.27%) subjects did not show borderline or strong secretion, respectively.
Conclusions: In naive subjects, low IgG titers are relatively long-lasting. Only a third of naive subjects maintain neutralizing responses. After specific stimulation, a very limited number of naive were unable to produce IFN-γ. The results attained in the small group of subjects with breakthrough infection suggest that simultaneous neutralizing antibody titers <20, binding antibody levels/ml <200, and IFN-γ <1,000 mIU/ml in subjects older than 58 may identify at-risk groups.
Keywords: IFN-γ; SARS-CoV-2; healthcare workers; humoral response; mRNA vaccines.
【저자키워드】 SARS-CoV-2, Healthcare workers, Humoral response, mRNA vaccines., IFN-γ, 【초록키워드】 neutralizing antibody, IgG, Vaccine, Immunity, Hospitalization, mRNA vaccine, T-cell Response, Infection, virus, mRNA vaccines, Protein, protective immunity, healthcare, age, Breakthrough infection, threshold, information, human serum, Delta VOC, Live virus, Neutralizing antibody titer, microneutralization, Neutralizing titer, Cytopathic effect, IgG titer, humoral, binding antibody, Dilution, Predictive, Volume, Older, stages, subject, secretion, domain, IgG levels, Wuhan strain, neutralized, neutralizing responses, BNT162b, enrolled, highest, shown, tested, identify, remained, evaluated, was determined, subjects, long-lasting, maintain, individuals, groups, all subject, IgG level, 【제목키워드】 response, worker, second, BNT162b, Day,